Corvus Pharmaceuticals (CRVS) Competitors

$12.21 -0.10 (-0.81%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$12.17 -0.04 (-0.35%)

As of 07:29 AM Eastern

CRVS vs. GRFS, APLS, APGE, CRSP, and DNTH

Should you buy Corvus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corvus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corvus Pharmaceuticals include Grifols (GRFS), Apellis Pharmaceuticals (APLS), Apogee Therapeutics (APGE), CRISPR Therapeutics (CRSP), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry.

How does Corvus Pharmaceuticals compare to Grifols?

Grifols (NASDAQ:GRFS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Grifols has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to Corvus Pharmaceuticals' net margin of 0.00%. Grifols' return on equity of 6.21% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Grifols has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.63	$454.82M	$0.19	41.42
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Grifols currently has a consensus price target of $10.00, indicating a potential upside of 27.06%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 173.00%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Corvus Pharmaceuticals had 15 more articles in the media than Grifols. MarketBeat recorded 17 mentions for Corvus Pharmaceuticals and 2 mentions for Grifols. Corvus Pharmaceuticals' average media sentiment score of -0.07 beat Grifols' score of -0.17 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Corvus Pharmaceuticals beats Grifols on 8 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Apellis Pharmaceuticals?

Apellis Pharmaceuticals (NASDAQ:APLS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Corvus Pharmaceuticals' net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Apellis Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Apellis Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

In the previous week, Corvus Pharmaceuticals had 11 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 17 mentions for Corvus Pharmaceuticals and 6 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.27 beat Corvus Pharmaceuticals' score of -0.07 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apellis Pharmaceuticals presently has a consensus price target of $35.72, suggesting a potential downside of 12.94%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 173.00%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Apellis Pharmaceuticals beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Apogee Therapeutics' return on equity of -32.64% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

In the previous week, Corvus Pharmaceuticals had 14 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Corvus Pharmaceuticals and 3 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.77 beat Corvus Pharmaceuticals' score of -0.07 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Apogee Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Apogee Therapeutics presently has a consensus target price of $112.73, suggesting a potential upside of 43.15%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 173.00%. Given Corvus Pharmaceuticals' higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Apogee Therapeutics beats Corvus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

In the previous week, Corvus Pharmaceuticals had 13 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 17 mentions for Corvus Pharmaceuticals and 4 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.66 beat Corvus Pharmaceuticals' score of -0.07 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Corvus Pharmaceuticals has lower revenue, but higher earnings than CRISPR Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,334.36	-$581.60M	-$6.22	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

CRISPR Therapeutics presently has a consensus target price of $65.47, indicating a potential upside of 34.82%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 173.00%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Corvus Pharmaceuticals has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Summary

CRISPR Therapeutics beats Corvus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Dianthus Therapeutics?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Dianthus Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Dianthus Therapeutics	$2.04M	2,240.40	-$162.34M	-$4.13	N/A

Corvus Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Corvus Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

In the previous week, Corvus Pharmaceuticals had 14 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 17 mentions for Corvus Pharmaceuticals and 3 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.81 beat Corvus Pharmaceuticals' score of -0.07 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 173.00%. Dianthus Therapeutics has a consensus target price of $117.82, suggesting a potential upside of 40.93%. Given Corvus Pharmaceuticals' higher probable upside, research analysts plainly believe Corvus Pharmaceuticals is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Dianthus Therapeutics beats Corvus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04B	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-23.48	18.13	20.64	25.23
Price / Sales	N/A	289.87	554.85	79.36
Price / Cash	97.12	55.27	27.48	37.30
Price / Book	16.73	6.57	9.66	6.63
Net Income	-$15.28M	$24.35M	$3.56B	$335.59M
7 Day Performance	-23.54%	-2.53%	-1.65%	-1.20%
1 Month Performance	-27.06%	-3.55%	-2.60%	-1.16%
1 Year Performance	237.29%	53.51%	30.07%	28.10%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	2.2542 of 5 stars	$12.21 -0.8%	$33.33 +173.0%	+238.2%	$1.04B	N/A	N/A	30	Analyst Revision
GRFS Grifols	4.568 of 5 stars	$7.56 -3.1%	$10.00 +32.3%	+1.4%	$5.31B	$8.51B	39.79	25,247	Analyst Downgrade
APLS Apellis Pharmaceuticals	1.814 of 5 stars	$41.06 +0.1%	$35.72 -13.0%	+135.1%	$5.25B	$1.00B	40.26	770	Positive News Analyst Upgrade
APGE Apogee Therapeutics	2.7383 of 5 stars	$82.93 -2.0%	$112.73 +35.9%	+93.9%	$5.23B	N/A	N/A	91
CRSP CRISPR Therapeutics	3.2434 of 5 stars	$52.83 -2.2%	$66.06 +25.0%	+25.3%	$5.21B	$3.51M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. GRFS, APLS, APGE, CRSP, and DNTH

How does Corvus Pharmaceuticals compare to Grifols?

Summary

How does Corvus Pharmaceuticals compare to Apellis Pharmaceuticals?

Summary

How does Corvus Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Dianthus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. GRFS, APLS, APGE, CRSP, and DNTH

How does Corvus Pharmaceuticals compare to Grifols?

Do insiders and institutionals have more ownership in GRFS or CRVS?

Which has more risk and volatility, GRFS or CRVS?

Is GRFS or CRVS more profitable?

Which has preferable earnings and valuation, GRFS or CRVS?

Do analysts prefer GRFS or CRVS?

Does the media refer more to GRFS or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Apellis Pharmaceuticals?

Do institutionals and insiders hold more shares of APLS or CRVS?

Is APLS or CRVS more profitable?

Which has preferable valuation & earnings, APLS or CRVS?

Which has more volatility & risk, APLS or CRVS?

Does the media favor APLS or CRVS?

Do analysts prefer APLS or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Apogee Therapeutics?

Is APGE or CRVS more profitable?

Does the media refer more to APGE or CRVS?

Do insiders and institutionals hold more shares of APGE or CRVS?

Which has better earnings & valuation, APGE or CRVS?

Which has more risk & volatility, APGE or CRVS?

Do analysts recommend APGE or CRVS?

Summary

How does Corvus Pharmaceuticals compare to CRISPR Therapeutics?

Does the media favor CRSP or CRVS?

Which has more risk & volatility, CRSP or CRVS?

Do institutionals and insiders believe in CRSP or CRVS?

Which has higher earnings and valuation, CRSP or CRVS?

Do analysts rate CRSP or CRVS?

Is CRSP or CRVS more profitable?

Summary

How does Corvus Pharmaceuticals compare to Dianthus Therapeutics?

Which has better valuation & earnings, CRVS or DNTH?

Is CRVS or DNTH more profitable?

Which has more volatility & risk, CRVS or DNTH?

Does the media prefer CRVS or DNTH?

Do analysts recommend CRVS or DNTH?

Do insiders & institutionals hold more shares of CRVS or DNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools